Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
102.3 USD | +0.24% |
|
-2.17% | -6.63% |
Jun. 27 | Barclays Trims Price Target on Revvity to $115 From $116 | MT |
Jun. 20 | Bionano Genomics Says Revvity to Commercialize VIA Software | MT |
Evolution of the average Target Price on Revvity, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Revvity, Inc.
TD Cowen | |
JPMorgan Chase | |
Baird | |
Bernstein | |
Nephron Research | |
KeyBanc Capital Markets | |
Raymond James | |
BofA Securities | |
Barclays | |
UBS | |
Evercore ISI | |
Wells Fargo Securities | |
Goldman Sachs | |
Citigroup | |
Stifel Nicolaus | |
Cowen | |
Credit Suisse | |
BMO Capital | |
Wolfe Research |
EPS Revisions
- Stock Market
- Equities
- RVTY Stock
- Consensus Revvity, Inc.